Sensorion Sas · EURONEXT:ALSEN
Sensorion Sas — Sensorion — Investor Presentation (September 2026)
33 slides from Sensorion Sas's investor presentation, September 2026
Slide 1: Developing next generation solutions to address hearing disorders
Developing next generation solutions to address hearing disorders Restore Treat Prevent Euronext Growth: ALSEN
Slide 2: Disclaimer
Disclaimer This document has been prepared by Sensorion (the “Company”) and is provided for This document contains certain forward-looking statements. These statements are not information purposes only. This document does not purport to contain comprehensive or guarantees of the Company’s future per
Slide 3: Sensorion at a glance
Sensorion at a glance The inner-ear specialist: building leadership across the full spectrum of hearing loss disorders. Expertise Lead program Second asset Shareholder base Inner-ear know-how SENS-601 SENS-401 Blue-chip healthcare specialist investors Inner-ear drug development Gene therapy candidat
Slide 4: Pipeline: leading player in GJB2
Pipeline: leading player in GJB2 Program Preclinical Phase I/II Phase III Next steps CTA approved in France; submitted in Canada. GJB2 (DFNB1A) HL: US IND and Australia CTA congenital onset submission (YE 2026). First patient dosing in France SENS-601 * targeted by early 2027. GJB2 (DFNB1A) HL: Prec
Slide 5: Recent highlights and upcoming milestones
Recent highlights and upcoming milestones ✓ Achieved Expected ✓ January 2026 ✓ May 2026 ✓ June 2026 ✓ August 2026 Expected Q4 2026 → 2027 €60 million financing Preclinical package New chief executive CTA cleared in US IND, Australia CTA completed presented at ASGCT appointed France; submitted in and
Slide 6: RESTORE
RESTORE SENS-601 for GJB2-related congenital hearing loss
Slide 7: The role of Connexin 26 (Cx26) in the cochlea
The role of Connexin 26 (Cx26) in the cochlea Cx26, encoded by GJB2 gene, is the predominant connexin in the cochlea, where it forms gap junctions between non-sensory supporting cells. Those gap junctions enable metabolite exchange and potassium recycling that sustain the electrochemical gradient dr
Slide 8: Mechanism of action of SENS-601 restoring CX26 expression
The mechanism of action of SENS-601 is designed to restore CX26 expression in cochlear supporting cells >100 GJB2 recessive mutations described to date, with SENS-601 designed as a single- construct approach across GJB2 variants Severity of hearing loss correlates with the degree of GJB2 loss of fun
Slide 9: Initial market opportunity
Initial market opportunity Widespread newborn screening and advances in early GJB2 (DFNB1A) HL: congenital onset genetic testing continue to improve the identification Illustrative management estimate and characterization of children with GJB2-related hearing loss. Births per year in the US, EU4 and
Slide 10: The inner ear as a gene therapy target
The inner ear as a gene therapy target 01 Direct local administration to target cells, with limited biodistribution outside the inner ear 02 Immunologically protected by the blood–labyrinth barrier 03 Low volume and low viral particle count versus systemic approaches 04 Durable activity from a singl
Slide 11: Sensorion core development capabilities
Sensorion core development capabilities 01 02 03 04 05 Differentiated Validated surgical Manufacturing Clinical execution HL strategic biological approach technique experience connectivity Pan-GJB2 approach, Dual-fenestration CDMO partnership for Operational experience Global network of designed to
Slide 12: Construct design
Construct design AAV-DJ capsid with broad tropism for cochlear Cassette combining a constitutive 5' promoter, the Sequence complementary to miR-183, present in supporting cells. Cx26 coding sequence and a proprietary sensory hair cells but not in supporting cells, regulatory sequence in the 3' UTR,
Slide 13: Surgical delivery approach
Surgical delivery approach Dual-fenestration technique combines two familiar procedures, cochlear implantation and stapedotomy, and is designed to minimize overpressure and backflow. Designed to maximize vector distribution and target cell exposure along the full length of the cochlea, allowing wide
Slide 14: Tropism and selectivity to Cx26-expressing target cells in NHP
Tropism and selectivity to Cx26-expressing target cells in NHP Three weeks after a single intracochlear injection: No transgene expression extensive transduction of the supporting cells that in the sensory hair cells naturally express GJB2 observed along the tonotopic axis of the cochlea. No transge
Slide 15: Cx26 knock-out mouse model
Cx26 knock-out mouse model Proprietary model generated and characterized in-house; conditional design circumvents the embryonic lethality of complete biallelic GJB2 loss. Early inactivation in utero, while the inner ear develops, reproduces the pathophysiology of DFNB1A, the most common form of GJB2
Slide 16: Hearing restoration in Cx26 knock-out mice
Hearing restoration in Cx26 knock-out mice Hearing improvement observed as early as three weeks after injection, across all tested frequencies. Demonstrated across multiple dose levels, with a therapeutic dose selected for further development. Replicated across multiple research and development manu
Slide 17: Restoration of functional Cx26 gap junctions in vitro
Restoration of functional Cx26 gap junctions in vitro Propidium iodide, in red, is a fluorescent dye HeLa DH cells lacking Cx26, or carrying a Cells transduced with SENS-601 took up dye that cannot cross intact cell membranes, so mutated Cx26, showed no dye transfer. across all three variants tested
Slide 18: Toxicology findings in NHP and mice
Toxicology findings in NHP and mice NHP study Three- and six-month arms, single Mouse study Three- and six-month arms, intracochlear injection intravenous injection Mortality None None Clinical pathology Minor non-adverse change in one parameter Slight change in one parameter, not associated with pa
Slide 19: Summary
Summary Activity to date Near-term milestones Preclinical proof-of-concept and tolerability package US IND and Australia CTA submission Presented at ASGCT 2026 Expected by end of 2026 CTA cleared in France, submitted in Canada Phase I/II trial initiation Congenital onset; Fast Track granted in Franc
Slide 20: TREAT & PREVENT
TREAT & PREVENT SENS-401 across multiple sensorineural hearing loss disorders
Slide 21: SENS-401: an oral otoprotectant candidate
SENS-401: an oral otoprotectant candidate Orphan drug designation Orally available small molecule, the (R)-enantiomer of azasetron, with a EMA1 and FDA2 dual mechanism: 5-HT₃ receptor antagonism with calcineurin- inhibitory activity. Pediatric investigation plan Designed to protect inner-ear sensory
Slide 22: SENS-401 data package across three indications
SENS-401 data package across three indications Hearing preservation after Cisplatin-induced ototoxicity Sudden sensorineural hearing cochlear implantation loss Positive Phase IIa: 25 of 28 randomized Phase IIa completed: 47 randomized Phase IIb (AUDIBLE-S): 115 randomized patients implanted Complete
Slide 23: CORPORATE OVERVIEW
CORPORATE OVERVIEW Team, governance and financial position
Slide 24: Leadership team
Leadership team Fred Chereau Laurent Desire Stephanie Filipe Valérie Salentey Bernd Schmidt Chief Executive Officer Head of Preclinical Head of Business Ops Head of Regulatory Chief Technical Officer and Portfolio Affairs and Quality Management Assurance At Sensorion since 2026. At Sensorion since 2
Slide 25: Board of directors
Board of directors Amit Munshi Chairman of the Board, USA Khalil Barrage USA Health Opportunities* Represented by Eric de la Julien Miara France Fortelle Switzerland Aniz Girach* UK Sofinnova Partners Represented by Cédric Moreau, France Federico Mingozzi* USA Redmile Group Represented by Florian Re
Slide 26: Scientific advisory board
Scientific advisory board Pr Christine Petit Pr Alain Fischer Dr Robert Dow Chair of the SAB. Professor, Institut Professor, Collège de France, Chief Development Officer, Scendea, Pasteur, Hearing Institute/ Institut France UK reConnect, France Pr Paul Avan Dr Diane Lazard Dr Hernán López-Schier Cen
Slide 27: Anticipated milestones
Anticipated milestones Program H2 2026 2027 SENS-601: congenital Phase I/II trial initiation; dosing of the first patient targeted CTA approved in France; Canadian CTA under review; US by early 2027, with clinical data generation expected onset IND and Australia CTA submission throughout 2027 SENS-6
Slide 28: Value proposition
Value proposition On a mission to enable people with inner ear hearing disorders to live life with unlimited connections. Lead asset entering the clinic Positioned to disrupt a treatment Domain expertise and partnerships shortly, with a global development landscape with no approved strategy therapie
Slide 29: Thank you
Thank you contact@sensorion-pharma.com www.sensorion.com Copyright by Sensorion 2026. All Rights Reserved 29
Slide 30: Cx26 biology in detail
Cx26 biology in detail GJB2 gene, which encodes Cx26, is naturally expressed in the non- sensory supporting cells of the cochlea. Cx26 is the predominant connexin in the cochlea; its heteromeric or heterotypic hexamers form gap junctions. Cx26 is absent in sensory hair cells, where functional gap ju
Slide 31: Construct design in detail
Construct design in detail The transgene cassette comprises a promoter, a 5’ Cx26 coding sequence and a proprietary regulatory sequence in the 3’ untranslated region. The regulatory sequence is transcribed into mRNA complementary to miR-183, a small non-coding RNA occurring robustly in sensory inner
Slide 32: Gap junction permeability assay
Gap junction permeability assay c.35delG p.M34T p.V37I Untransduced HeLa DH cells are highly stable during electrophysiological testing, making them the industry standard for gap junction assays. c.35delG is a truncating mutation associated with severe-to- profound hearing loss; p.M34T and p.V37I ar
Slide 33: The hearing loss spectrum and standard of care
The hearing loss spectrum and standard of care Hearing aids amplify sound, but do not restore the Cochlear implants bypass the sensory epithelium Access and clarity are both required for a good clarity lost when the cochlear supporting cell entirely and are indicated only toward the severe- outcome.